Etentamig Meets Both CERVINO Endpoints

Company: AbbVie · Drug: Etentamig (BCMAxCD3 Bispecific) · Trial: CERVINO (Phase III) · Indication: Relapsed/Refractory Multiple Myeloma · Date: September 3, 2026 Summary AbbVie’s investigational BCMAxCD3 bispecific etentamig met both dual primary endpoints in the 393-patient Phase III CERVINO trial. Objective response was 74.0% versus…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Agenus Raises Up to $340M on Neoadjuvant MSS Colon Cancer
Infinimmune Raises $75 Million for Two Atopic-Dermatitis Antibodies
Regeneron – MFN Drug Pricing Agreement
Scribe Prices an Upsized $128.7 Million IPO